Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iDose TR in conjunction with cataract surgery
NCT06061718Phase 3Active, not recruiting
- Sponsor
- Glaukos Corporation
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Glaukos Corporation. Primary endpoint: Change from baseline in mean diurnal IOP at 3 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06061718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061718.